|
Market Closed -
Nasdaq
01:30:00 03/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 190.01 USD | +0.57% |
|
-4.46% | +544.32% |
| 02/10 | Nasdaq hits record high after softer jobs data tempers rate-hike bets | RE |
| 02/10 | Weak Jobs Lead to Stronger Stocks |  |
| Market Cap | 7.59TCr 6.74TCr 6.29TCr 5.73TCr 11TCr 7,29300Cr 11TCr 76TCr 29TCr 3,72800Cr 28TCr 28TCr 11,96500Cr | P/E 2026 * |
-22.7x | P/E 2027 * | -39.7x |
|---|---|---|---|---|---|
| Enterprise Value | 7.22TCr 6.42TCr 5.99TCr 5.46TCr 10TCr 6,94100Cr 10TCr 72TCr 28TCr 3,54900Cr 27TCr 27TCr 11,38800Cr | EV / Sales 2026 * |
34.4x | EV / Sales 2027 * | 30.3x |
| Free-Float |
92.66% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Tradegate
| 0QF | Real-time | |
|
Xetra
| 0QF | Delayed | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
Boerse Muenchen
| 0QF | Real-time | |
|
CBOE
| Real-time | ||
|
CBOE
| 0A45 | Real-time | |
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
London S.E.
| 0A45 | Delayed | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
Lima
| MRNAUS | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript: Moderna, Inc.
| 1 day | +0.57% | ||
| 1 week | -4.46% | ||
| Current month | -1.33% | ||
| 1 month | +30.55% | ||
| 3 months | +138.23% | ||
| 6 months | +286.20% | ||
| Current year | +544.32% |
| 1 week | 183.28 |  | 208.9 |
| 1 month | 130.38 | | 208.9 |
| Current year | 29.81 | | 208.9 |
| 1 year | 22.28 | | 208.9 |
| 3 years | 22.28 | | 208.9 |
| 5 years | 22.28 | | 376.65 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 01/03/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 06/09/2022 |
Stephen Hoge
PSD | President | 50 | 01/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 01/02/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 01/03/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 11/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/09/26 | Exercice | Chairperson | 1,93,185 | 0.0484% | ||
| 10/09/26 | Exercice | Chief Financial Officer | 74,508 | 0.0187% | ||
| 04/09/26 | Exercice | General Counsel | 29,298 | 0.0073% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.57% | -4.46% | +566.94% | +82.25% | 7.59TCr | |
| -0.61% | -3.43% | +36.07% | +115.04% | 1,01900Cr | |
| -1.02% | -5.60% | +35.72% | +64.63% | 62TCr | |
| +1.11% | -0.58% | +12.36% | +77.95% | 46TCr | |
| +0.34% | -3.01% | +61.79% | +41.24% | 36TCr | |
| -0.95% | -4.05% | +20.54% | +41.71% | 33TCr | |
| -1.46% | -2.89% | +10.57% | +32.81% | 27TCr | |
| -1.35% | -5.43% | -6.17% | +8.98% | 24TCr | |
| -1.04% | -2.79% | +35.30% | +51.84% | 22TCr | |
| -1.87% | -4.10% | +28.44% | +93.66% | 18TCr | |
| Average | -0.63% | -3.63% | +80.16% | +61.01% | 37.73TCr | |
| Weighted average by Cap. | -0.57% | -3.56% | +39.89% | +70.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 210.12Cr 186.69Cr 174.24Cr 158.82Cr 299.53Cr 20TCr 302.31Cr 2.11TCr 817.1Cr 10TCr 788.88Cr 771.76Cr 33TCr | 243.39Cr 216.25Cr 201.84Cr 183.97Cr 346.96Cr 23TCr 350.19Cr 2.44TCr 946.51Cr 12TCr 913.82Cr 893.98Cr 38TCr |
| Net income | -331.13Cr -294.21Cr -274.6Cr -250.29Cr -472.04Cr -32TCr -476.43Cr -3.32TCr -1.29TCr -16TCr -1.24TCr -1.22TCr -52TCr | -194.66Cr -172.96Cr -161.43Cr -147.13Cr -277.49Cr -19TCr -280.08Cr -1.95TCr -756.99Cr -9.57TCr -730.85Cr -714.99Cr -31TCr |
| Net Debt | -365.28Cr -324.56Cr -302.92Cr -276.1Cr -520.72Cr -35TCr -525.57Cr -3.67TCr -1.42TCr -18TCr -1.37TCr -1.34TCr -58TCr | -216.99Cr -192.8Cr -179.94Cr -164.01Cr -309.33Cr -21TCr -312.21Cr -2.18TCr -843.84Cr -11TCr -814.7Cr -797.01Cr -34TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $190.01 | +0.57% | 1,02,89,461 |
| 01/26/01 | $188.94 | -1.89% | 1,54,37,001 |
| 30/26/30 | $192.57 | -5.35% | 2,06,49,483 |
| 29/26/29 | $203.46 | +3.13% | 1,32,77,922 |
| 28/26/28 | $197.28 | -0.80% | 1,33,59,640 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
